Fig. 8.

Napabucasin can prevent IL-11-induced HCC outgrowth in vivo.

(a) Schematic representation of the HCC model. A single injection of Hepa1–6 cells (1·5 × 10 [6]) was administered into the livers of mice, followed by two doses of IL-11 (200 μg/kg) with or without napabucasin (40 mg/kg) on days 5 and 7. (b) Representative pictures of HCC on day 14 from control mice (above), mice treated with IL-11 (middle), and mice treated with IL-11 and napabucasin (below). n = 5 for each group. Data are representative of three independent experiments. Scale bar, 1 cm. (c) Ratio of liver weight to body weight calculated for the indicated groups at autopsy. n = 5 for each group. The results are expressed as mean ± SEM. *p < 0·05 (unpaired Student's t-test). (d) Liver damage and fibrosis as assessed by HE and Masson trichrome staining. Scale bars, 400 μm. (e) Representative images of IHC staining of PCNA in tissue sections from the microenvironment of tumours from mice from the indicated groups. Original magnifications: ×10, ×40; scale bars, 100 μm. (f) Representative images of IHC staining of AFP in tissue sections in the tumour microenvironment of tumours from mice from the indicated groups. Original magnifications: ×2·5, ×40; scale bars, 100 μm. For (e) and (f), data are representative of three independent experiments.